Cancer cells are gluttons. Researchers have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumour cells are also characterized by a series of features such as mobility or unlikeliness to join in an ordered set. Researchers are calling this behaviour ‘mesenchymal,’ and they suspect it promotes metastasis.
At EPFL, a research team was able to demonstrate that the two observations, appetite for sugar and mesenchymal behaviour, result from the same mechanism, at least in non-small cell lung cancer. They also showed that the intensity of the phenomenon significantly influenced the chances of patient survival. Published in Cancer & Metabolism, this discovery opens up new potential targets for future therapies.
Mesenchymal behaviour is not in itself an anomaly. During embryonic development, some cells acquire these characteristics. In adults, a few cells retain this disposition. Mesenchymal behaviour is quite a useful feature, but it’s abnormally reactivated in non-small cell lung cancer in the current study.
The mesenchymal cancer cells studied by the researchers produce a protein called GLUT3. The latter serves the function of capturing glucose to activate various growth processes. This is the protein responsible for meeting the cell’s need for sugar.
By artificially inducing mesenchymal behaviour in cancer cells, the researchers found that the cells spontaneously produced GLUT3. This observation clearly shows that the same mechanism is at work. This shift from one behaviour to another, called epithelial-mesenchymal transition, is a highly debated issue. The team have clearly established a cause and effect relationship between this transition and the glucose consumption of cancer cells.
Lung tumour cells produce widely varying amounts of GLUT3. This is because the gene is itself regulated by an element called ZEB1, and the amount of the latter is a function of many causes. These variations in the amounts of GLUT3 seem to be a strong indicator of the aggressiveness of the tumour. By analyzing data from 450 patients with metastatic non-small cell lung cancer, researchers were able to show that the larger the quantity of GLUT3, the lower the chances of survival.
Patients were diagnosed relatively early and were followed for several years. Depending on whether they produced high or low amounts of GLUT3, their survival rates over seven years spanned almost 20%. The data didn’t permit the team to conclude that the mechanism promotes metastasis, but greatly reinforces the theory.
The discovery identifies a potential target for future medications. For example, a toxic molecule that could be specifically incorporated by GLUT3 to destroy the cell from within. Protected by the blood-brain barrier, neurons that also produce GLUT3 would not be affected.
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.